Tumor-Infiltrating Lymphocyte

It took more than 35 years for tumor-infiltrating lymphocytes, which Steven A. Rosenberg, MD, PhD, and colleagues first reported on in 1988 for the treatment of advanced melanoma, to progress enough to gain FDA approval.

Clinicians treating patients with tumor-infiltrating lymphocytes should closely monitor toxicities associated with interleukin-2 and halt administration of the drug if necessary, according to the first guidelines regarding the therapy.

The FDA placed a clinical hold on a trial designed to evaluate a novel cell therapy for non-small cell lung cancer after one study participant died.

Three of six women with metastatic breast cancer who received investigational tumor-infiltrating lymphocytes plus pembrolizumab demonstrated tumor reductions greater than 50%, according to phase 2 study results.

Nearly a quarter of patients with heavily pretreated non-small cell lung cancer achieved an objective response to an infusion of LN-145, according to study results presented at Society for the Immunotherapy of Cancer Annual Meeting.

A lower dose of cyclophosphamide during preconditioning prior to tumor-infiltrating lymphocyte infusion appeared comparably effective but less toxic than a higher dose, according to results published in Journal for ImmunoTherapy of Cancer.

Lifileucel induced high response rates among patients with advanced melanoma whose disease progressed on immune checkpoint and BRAF/MEK inhibitors, according to study results presented during the ASCO20 Virtual Scientific Program.

The addition of stereotactic body radiotherapy after progression on pembrolizumab prolonged PFS among patients with metastatic non-small cell lung cancer, according to results of a prospective phase 2 study presented during the plenary session of American Society for Radiation Oncology Annual Meeting.